Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-414-0
CAS number: 814-94-8
Summary data are presented below:
Group Exposure level (μg/L) Particle size
Target Achieved MMAD (μm) sg
2 2.3 2.44 3.0 2.54
3 9.1 9.19 3.0 2.41
4 80 87.9 2.7 2.44
MMAD Mass median aerodynamic diameter
sg Geometric standard deviation
The achieved levels were 106, 101 and 110% of the target concentrations
for Groups 2, 3 and
4 respectively. The Mass Median Aerodynamic Diameters for Groups 2, 3
and 4 are within
the ideal range (1-3 μm) for a repeat dose inhalation study.
There were no treatment related clinical signs observed during the
detailed weekly physical
Lower body weight gain was evident for males exposed to 9.19 μg/L and
87.9 μg/L and for
all females exposed to tin monoxide. Food consumption was also slightly
reduced for males
exposed to 87.9 μg/L.
A statistically significant increase in group mean activated partial
thromboplastin times were
evident for males exposed to 9.19 and 87.9 μg/L and all females exposed
to tin monoxide.
Group mean venous blood oxygen saturation levels were increased for
females exposed to
9.19 μg/L and both sexes exposed to 87.9 μg/L.
Two hours after the completion of exposure in Week 4, tin was detected
in the plasma of a
single male and female exposed to 9.19 μg/L and in all animals exposed
to 87.9 μg/L. Tin
was not quantifiable in control animals or animals exposed to 2.44 μg/L.
Group mean lung and bronchi weights (adjusted for terminal body weight)
were greater than
control for all animals exposed to tin monoxide.
Histopathological changes related to treatment were observed within the
accumulation of pigmented and flocculent material within alveoli,
variably accompanied by
both diffuse and local aggregations of alveolar macrophages, and
increased cellularity of the
BALT), tracheobronchial and mediastinal lymph nodes (increased general
cellularity, with or
without the accumulation of pigmented material), larynx (pigment
accumulation within the
epithelium and lamina propria) and kidneys (increased tubular pigment).
the larynx and lungs were considered to reflect the accumulation of
inhaled test article, with
attempted clearance by the local mononuclear-phagocyte system.
within the local lymph nodes and kidneys were considered to represent
systemic dissemination of test article. Findings were more pronounced,
in terms of incidence
and severity, amongst animals dosed with 87.9 μg/L, and displayed a
response. Amongst animals dosed with 2.44 μg/L, findings were restricted
to the lungs and
tracheobronchial lymph nodes
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again